Von Willebrand Disease (VWD) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Von Willebrand Disease Emerging Therapy and TPP Insights

Thelansis’s “Von Willebrand Disease (VWD) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Von Willebrand Disease Overview

Von Willebrand disease is an inherited bleeding disorder caused by quantitative deficiency or qualitative dysfunction of von Willebrand factor, impairing platelet adhesion and, in some patients, factor VIII stability. Clinical severity varies widely, ranging from mild mucosal bleeding to severe recurrent hemorrhage. Current treatment includes desmopressin in responsive patients, VWF-containing concentrates, antifibrinolytic therapy, and prophylaxis for selected patients with severe or frequent bleeding. The therapeutic landscape has already advanced beyond episodic plasma-derived replacement: recombinant VWF vonicog alfa is FDA-approved for routine prophylaxis in adults with all VWD types, following a 2025 indication expansion, while Wilate received a further FDA expansion in 2026 to include routine prophylaxis in children younger than 6 years. These advances are shifting development toward reducing treatment frequency and infusion burden while maintaining sustained hemostatic protection. Emerging approaches include agents that prolong VWF exposure, such as HMB-002, targeted therapies such as rondoraptivon pegol for selected type 2B disease, and hemostatic rebalancing strategies such as VGA039. These approaches remain investigational, but they broaden the field beyond direct VWF replacement. For stakeholders, VWD represents a high-value rare-hematology opportunity where the next advances are likely to combine longer duration, less burdensome administration, and mechanism-specific hemostatic control.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)